What is the BLUEPRINT Study?
The BLUEPRINT Study is a world-first, groundbreaking project led by researchers in Melbourne, Australia. It will follow 550 babies born prematurely (before 32 weeks of pregnancy) from birth until the age of 2 years old.
The study aims to understand how the lungs of premature babies function in the first week after birth, using advanced methods to closely examine their lung health. Researchers will then continue to monitor and follow the babies' lung development until they're 2 years old.
This study is funded by a National Health and Medical Research Council (NHMRC) Clinical Trials and Cohort Studies grant, covering 5 years of research.
Recruitment of the first babies began in December 2024.
140 babies enrolled!
Thank you to the kind and generous families for agreeing to take part in this promising study.
Sponsored by the Murdoch Children’s Research Institute (MCRI), the BLUEPRINT Study and will be conducted in at least 5 hospitals that care for premature babies in Victoria, Australia.
Key Facts
- Very premature babies have a high risk of long-term lung disease (chronic lung disease)
- Often clinicians do not have the tools to know which treatment is the best for the lungs of a specific premature baby
- The BLUEPRINT Study will help clinicians to give the right treatment to the right baby at the right time, allowing clinicians to deliver the precision care needed to help premature babies.
- This clinical study has been initiated by an Australian collaboration of doctors caring for premature babies and scientists working to improve our understanding of lung health.
Our partners
